Your browser doesn't support javascript.
loading
Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma, Valentine U; Kose, Nurgun; Sather, D Noah; Sapparapu, Gopal; Falk, Rachel; King, Hannah; Singh, Vidisha; Lampley, Rebecca; Malherbe, Delphine C; Ditto, Noah T; Sullivan, Jonathan T; Barnes, Trevor; Doranz, Benjamin J; Labranche, Celia C; Montefiori, David C; Kalams, Spyros A; Haigwood, Nancy L; Crowe, James E.
Afiliación
  • Chukwuma VU; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Kose N; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Sather DN; Center for Infectious Disease Research, Seattle, Washington, United States of America.
  • Sapparapu G; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Falk R; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • King H; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Singh V; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Lampley R; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Malherbe DC; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
  • Ditto NT; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
  • Sullivan JT; Carterra Inc., Salt Lake City, Utah, United States of America.
  • Barnes T; Integral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
  • Doranz BJ; Integral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
  • Labranche CC; Integral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
  • Montefiori DC; Division of Surgical Sciences, Duke University, Durham, North Carolina, United States of America.
  • Kalams SA; Division of Surgical Sciences, Duke University, Durham, North Carolina, United States of America.
  • Haigwood NL; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Crowe JE; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
PLoS One ; 13(12): e0209437, 2018.
Article en En | MEDLINE | ID: mdl-30566528
ABSTRACT
Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus type 1 (HIV-1) vaccine designs, but the presence of bNAbs in naturally infected individuals may be associated with high plasma viral loads, suggesting that the magnitude, duration, and diversity of viral exposure may contribute to the development of bNAbs. Here, we report the isolation and characterization of a panel of human monoclonal antibodies (mAbs) from two subjects who developed broadly neutralizing autologous antibody responses during HIV-1 infection. In both subjects, we identified collections of mAbs that exhibited specificity only to a few autologous envelopes (Envs), with some mAbs exhibiting specificity only to a subset of Envs within the quasispecies of a particular sample at one time point. Neutralizing antibodies (NAbs) isolated from these subjects mapped mostly to epitopes in the Env V3 loop region and the CD4 binding site. None of the individual neutralizing mAbs recovered exhibited the cumulative breadth of neutralization present in the serum of the subjects. Surprisingly, however, the activity of polyclonal mixtures comprising individual mAbs that each possessed limited neutralizing activity, could achieve increased breadth of neutralizing activity against autologous isolates. While a single broadly neutralizing antibody targeting one epitope can mediate neutralization breadth, the findings presented here suggest that a cooperative polyclonal process mediated by diverse antibodies with more limited breadth targeting multiple epitopes also can achieve neutralization breadth against HIV-1.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Anticuerpos Neutralizantes Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Anticuerpos Neutralizantes Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos